Endo Par Innovation Co. LLC—better known as EPIC—accused generic drug maker Belcher Pharmaceuticals LLC and its BPI Labs LLC unit of copying EPIC’s formula for stable injectable epinephrine, a life-saving medication for people suffering severe allergic reactions.
EPIC and sister companies Par Pharmaceutical Inc. and Par Sterile Products LLC asked for a court order blocking its rival from making or selling in the United States a generic version of its drug until the companies’ patents on the formulation and labeling expire, according to a complaint filed Tuesday in the US District Court for the Middle District of Florida.
EPIC and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.